Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach

Background Neuroendocrine neoplasms most commonly metastasize to the liver. Operative extirpation of neuroendocrine neoplasm hepatic metastases improves symptoms and seems to improve survival, but subsequent evidence is required. The current study evaluates the progression-free survival and overall...

Full description

Saved in:
Bibliographic Details
Published in:Surgery 2011-02, Vol.149 (2), p.209-220
Main Authors: Saxena, Akshat, BMedSc, Chua, Terence C., BScMed (Hons), MBBS, Sarkar, Anik, Chu, Francis, MBBS, FRACS, Liauw, Winston, MBBS, MMedSci, FRACP, Zhao, Jing, MD, Morris, David L., MD, PhD
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Disease-Free Survival
Female
General aspects
Hepatectomy - methods
Humans
Liver Neoplasms - mortality
Liver Neoplasms - secondary
Liver Neoplasms - surgery
Male
Medical sciences
Middle Aged
Neoplasm Staging
Neuroendocrine Tumors - mortality
Neuroendocrine Tumors - pathology
Neuroendocrine Tumors - surgery
Prognosis
Surgery
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Neuroendocrine neoplasms most commonly metastasize to the liver. Operative extirpation of neuroendocrine neoplasm hepatic metastases improves symptoms and seems to improve survival, but subsequent evidence is required. The current study evaluates the progression-free survival and overall survival of patients after resection (with or without ablation) of neuroendocrine neoplasm hepatic metastases. As a secondary endpoint, the prognostic factors associated with progression-free survival and overall survival were evaluated. Methods Seventy-four patients with neuroendocrine neoplasm hepatic metastases underwent hepatic resection between December 1992 and December 2009. Thirty-eight patients underwent synchronous cryoablation. Patients were assessed radiologically and serologically at monthly intervals for the first 3 months and then at 6-month intervals after treatment. Progression-free survival and overall survival were determined; clinicopathologic and treatment-related factors associated with progression-free survival and overall survival were evaluated through univariate and multivariate analyses. Results No patient was lost to follow-up. The median follow-up for the patients who were alive was 41 months (range, 1–162). The median progression-free survival and overall survival after hepatic resection were 23 and 95 months, respectively. Five- and 10-year overall survival were 63% and 40%, respectively. Two independent factors were associated with overall survival: histologic grade ( P  
ISSN:0039-6060
1532-7361
DOI:10.1016/j.surg.2010.06.008